Hi, A small drilling crew in a Utah desert punched nearly three miles into the
Earth's crust. What did they find? Absolutely shocking.



<[link removed]>



Сⅼіϲkhеrе and I'll reveal the shocking details.
<[link removed]>



Hi,

A small drilling crew in a Utah desert punched nearly three miles into the
Earth's crust.

What did they find?

Absolutely shocking.

<[link removed]>
This changes everything.

Click here to see
<[link removed]>

You have until October 20th.

 



Biotech M&A Is on Pace for Its Best Year Since 2019 — With Deal Value Already
Past $100 Billion and Eli Lilly Just Announcing Its Latest Acquisition —Even as
Rising Rates Make Dealmaking Harder Than Earlier This Year. Here Is What the
Buying Spree Means for Your Portfolio.




Biotech and pharma M&A has already topped $106 billion in deal value this
year, putting the industry on pace for more than$250 billion in total deals,
which would mark its strongest year since the 2019 peak, according to PitchBook
data cited by CNBC. The average deal size has jumped to roughly$527 million, up
from about $365 million in 2025, as large pharma companies lean on bolt-on
acquisitions in the $1 billion to $5 billion range to fill pipeline gaps
without taking on the integration risk of a full company purchase. Eli Lilly
extended its own acquisition streak on September 1 with a deal for Merida
Biosciences, a private biotech developing precision therapeutics for autoimmune
and allergic diseases, continuing a wave of consolidation that included a run
of radiopharmaceutical and rare-disease deals in August. Even so, HSBC's head
of life sciences research noted the deal-making environment has grown tougher
in the second half of the year as interest rates have moved higher than they
were earlier in 2026.




For your portfolio, an active M&A cycle like this one is generally good news
for smaller biotech companies with promising but unproven pipelines, since
acquisition premiums are one of the more reliable ways this sector generates
returns for early investors.If you hold individual clinical-stage biotech
names, the current environment makes them more plausible acquisition targets
than they were a year or two ago, though a tougher rate backdrop in the second
half of the year means large acquirers may become more selective about deal
size and structure going forward. Diversified biotech funds are generally a
lower-risk way to get exposure to this M&A wave than betting on any single
company being acquired, since picking the specific next target is genuinely
difficult even in an active dealmaking environment like this one.




Sources: CNBC / PitchBook, June 2026 · The Pharma Letter, September 2026




 

[email protected] is on PowerFieldNotes.com
<[link removed]> list because you opted in before the crowd
caught on.

If we go quiet — look in promotions, updates, or wherever your inbox files
things it hasn't figured out yet.

Unsubscribe
<[link removed]>
. We'll part ways cleanly.

If something's off, you can reach us here <mailto:[email protected]>.


<[link removed]>
Privacy Policy <[link removed]>.

254 Chapman Rd Ste 208 Newark, Delaware 19702.




 

© 2026 Alpha One Marketers LLC. All rights reserved.